What REGN ultimately might need is a trial with "as-needed" Lucentis vs. "as-needed" trap. I suspect that the trap would require significantly fewer injections over a multi-year period.
Exactly right, IMO. I’ve been saying for years that REGN’s AMD program was aiming too low, and I think this is now clear.